Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages S2-

  Maggio, Roberto ^a   Aloisi, Gabriella ^a   Silvano, Elena ^a   Rossi, Mario ^a   Millan, Mark J ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Adenylyl cyclase supersensitivity; Allosteric; Dopamine D1 and D3 receptors; Gambling; Heterodimer; Partial agonist

Indexed keywords

ADENYLATE CYCLASE; ANTIPARKINSON AGENT; APOMORPHINE; ARIPIPRAZOLE; BIFEPRUNOX; BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HETERODIMER; MONOMER; NEUROLEPTIC AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; PRECLAMOL; QUINPIROLE; ROPINIROLE; S 32504; S 33592; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; DRUG EFFICACY; DRUG POTENCY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIGAND BINDING; PARKINSON DISEASE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; ANIMAL; METABOLISM; PHYSIOLOGY; PROTEIN MULTIMERIZATION;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; RECEPTORS, DOPAMINE;

EID: 72649087941     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70826-0     Document Type: Article

References (60)

1. Maggio R., Innamorati G., and Parenti M. G protein-coupled receptor oligomerization provides the framework for signal discrimination. J Neurochem 103 (2007) 1741-1752
2. Franco R., Casadó V., Cortés A., Ferrada C., Mallol J., Woods A., et al. Basic concepts in G-protein-coupled receptor homo- and heterodimerization. ScientificWorldJournal 7 (2007) 48-57
3. Whorton M.R., Bokoch M.P., Rasmussen S.G., Huang B., Zare R.N., Kobilka B., et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci USA 104 (2007) 7682-7687
4. Maggio R., Novi F., Scarselli M., and Corsini G.U. The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology. FEBS J 272 (2005) 2939-2946
5. Milligan G., and Smith N.J. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28 (2007) 615-620
6. Ginés S., Hillion J., Torvinen M., Le Crom S., Casadó V., Canela E.I., et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97 (2000) 8606-8611
7. 2 receptors. J Biol Chem 277 (2002) 18091-18097
8. Torvinen M., Marcellino D., Canals M., Agnati L.F., Lluis C., Franco R., et al. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67 (2005) 400-407
9. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., and Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
10. 2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279 (2004) 35671-35678
11. Fiorentini C., Busi C., Gorruso E., Gotti C., Spano P., and Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74 (2008) 59-69
12. 3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276 (2001) 30308-30314
13. Maggio R., Scarselli M., Novi F., Millan M.J., and Corsini G.U. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 87 (2003) 631-641
14. Novi F., Millan M.J., Corsini G.U., and Maggio R. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. J Neurochem 102 (2007) 1410-1424
15. Neve K.A., Seamans J.K., and Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24 (2004) 165-205
16. 3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20 (2000) 8677-8684
17. 3 receptors as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90 (2001) 231-259
18. Joseph J.D., Wang Y.M., Miles P.R., Budygin E.A., Picetti R., Gainetdinov R.R., et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 112 (2002) 39-49
19. Surmeier D.J., Song W.J., and Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16 (1996) 6579-6591
20. 2 receptor expressing neurons. Neuropsychopharmacology 20 (1999) 60-80
21. Bennett Jr. J.P., and Piercey M.F. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 163 (1999) 25-31
22. Matheson A.J., and Spencer C.M. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 60 (2000) 115-137
23. Foley P., Gerlach M., Double K.L., and Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 111 (2004) 1375-1446
24. Millan M.J., Cussac D., Gobert A., Lejeune F., Rivet J.M., Mannoury la Cour C., et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. J Pharmacol Exp Ther 309 (2004) 903-920
25. 2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther 309 (2004) 921-935
26. 2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J Pharmacol Exp Ther 309 (2004) 936-950
27. Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin J.A., and Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303 (2002) 791-804
28. 2), receptor subtypes. J Pharmacol Exp Ther 303 (2002) 815-822
29. 2)-adrenoceptor. J Pharmacol Exp Ther 303 (2002) 805-814
30. Newman-Tancredi A., Cussac D., Audinot V., Pasteau V., Gavaudan S., and Millan M.J. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5′-O-(3-[35S]thio)-triphosphate binding and antibody study. Mol Pharmacol 55 (1999) 564-574
31. Cussac D., Newman-Tancredi A., Pasteau V., and Millan M.J. Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol 56 (1999) 1025-1030
32. 3 dopamine receptor. J Recept Signal Transduct Res 24 (2004) 117-130
33. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49 (1997) 231-252
34. Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease. Clin Neuropharmacol 18 Suppl 1 (1995) S195-S206
35. Tamminga C.A., and Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1 (2002) 141-147
36. Van Vliet B.J., Mos J., Van der Heijden J., Feenstra R., Kruse C.G., and Long S.K. DU-127090: a highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potential. Eur Neuropsychopharmacol 10 Suppl 3 (2000) S20-S34
37. 3 partial agonist. J Pharmacol Exp Ther 315 (2005) 1278-1287
38. 2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 1003 (2004) 9-17
39. Edwards N.C., Pesa J., Meletiche D.M., Engelhart L., Thompson A.K., Sherr J., et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 24 (2008) 3341-3355
40. Grunder G., Carlsson A., and Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60 (2003) 974-977
41. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci 29 (2008) 314-321
42. Inoue A., and Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol 86 (2001) 376-380
43. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289 (2000) 739-745
44. Fotiadis D., Liang Y., Filipek S., Saperstein D.A., Engel A., and Palczewski K. Atomic-force microscopy: Rhodopsin dimers in native disc membranes. Nature 421 (2003) 127-128
45. 2 receptor homodimer. J Biol Chem 278 (2003) 4385-4388
46. Guo W., Shi L., Filizola M., Weinstein H., and Javitch J.A. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 102 (2005) 17495-17500
47. Mesnier D., and Banères J.L. Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1. J Biol Chem 279 (2004) 49664-49670
48. Fotiadis D., Jastrzebska B., Philippsen B., Müller D.J., Palczewski K., and Engel A. Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. Curr Opin Sruct Biol 16 (2006) 252-259
49. Galvez T., Duthey B., Kniazeff J., Blahos J., Rovelli G., Bettler B., et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 20 (2001) 2152-2159
50. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 (1999) 697-700
51. Franco R., Ferré S., Agnati L., Torvinen M., Ginés S., Hillion J., et al. Evidence for adenosine/dopamine receptor interactions: indications for heterodimerization. Neuropsychopharmacology 23 4 Suppl (2000) S50-S59
52. Watts V.J., and Neve K.A. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacol Ther 106 (2005) 405-421
53. Varga E.V., Yamamura H.I., Rubenzik M.K., Stropova D., Navratilova E., and Roeske W.R. Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. Life Sci 74 (2003) 299-311
54. Seedat S., Kesler S., Niehaus D.J., and Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11 (2000) 185-186
55. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381
56. Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs 22 (2008) 407-416
57. Driver-Dunckley E.D., Noble B.N., Hentz J.G., Evidente V.G., Caviness J.N., Parish J., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30 (2007) 249-255
58. Heidbreder C. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 7 (2008) 410-421
59. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49 (2005) 77-105
60. Silverdale M.A., Nicholson S.L., Ravenscroft P., Crossman A.R., Millan M.J., and Brotchie J.M. Selective blockade of D(3) dopamine receptors enhances the antiparkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 188 (2004) 128-138